Search results for

Don't be fooled by Brett Goldstein's grumpy exterior – he can't resist a big, open-hearted story. He's learned that it's possible to love even the most annoying person if you look at them hard enough.

There's cause for concern. But how concerned should we be? Here's a rundown of the current thinking on key issues as transmission, severity of disease — and effectiveness of vaccines.

Matt has been a reporter at KUT off and on since 2006. He came to Austin from Boston, then went back for a while--but couldn't stand to be away--so he came back to Austin. Matt grew up in Maine (but hates lobster), and while it might sound hard to believe, he thinks Maine and Texas are remarkably similar.

If your doctor prescribes a GLP-1 medication for weight loss but your insurance won't cover it, you have options.

Steve Carmody has been a reporter for Michigan Radio since 2005. Steve previously worked at public radio and television stations in Florida, Oklahoma and Kentucky, and also has extensive experience in commercial broadcasting. During his two and a half decades in broadcasting, Steve has won numerous awards, including accolades from the Associated Press and Radio and Television News Directors Association. Away from the broadcast booth, Steve is an avid reader and movie fanatic.

TKTKTKTKTKKTKTKTKTKT (function(t,e,s,n){var o,a,c;t.SMCX=t.SMCX||[],e.getElementById(n)||(o=e.getElementsByTagName(s),a=o[o.length-1],c=e.createElement...

Taking the drug made one writer feel so sick she quit and focused on healthy habits instead of her body size. Turns out, 65% of people using GLP-1 drugs for weight loss quit within a year.

It will be a few years yet before Ohioans see how a constitutional change in the way Statehouse lawmakers districts are drawn plays out in the future....

A new survey of Americans across all income brackets captures some surprising views about their economic experience and expectations of success.

Jessica Chaikof says research into gene therapies could someday save her eyesight. But she worries cuts to federal research funding could mean that therapy won't be ready in time.